JP2009502922A - カスパーゼ阻害剤プロドラッグ - Google Patents
カスパーゼ阻害剤プロドラッグ Download PDFInfo
- Publication number
- JP2009502922A JP2009502922A JP2008523976A JP2008523976A JP2009502922A JP 2009502922 A JP2009502922 A JP 2009502922A JP 2008523976 A JP2008523976 A JP 2008523976A JP 2008523976 A JP2008523976 A JP 2008523976A JP 2009502922 A JP2009502922 A JP 2009502922A
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- membered
- aryl
- disease
- ring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- NURQLCJSMXZBPC-UHFFFAOYSA-N Cc1ccncc1C Chemical compound Cc1ccncc1C NURQLCJSMXZBPC-UHFFFAOYSA-N 0.000 description 1
- XPCYMUBTCGGWOH-UHFFFAOYSA-N Cc1cncnc1C Chemical compound Cc1cncnc1C XPCYMUBTCGGWOH-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Transplantation (AREA)
- Biotechnology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US70337505P | 2005-07-28 | 2005-07-28 | |
| PCT/US2006/028174 WO2007015931A2 (en) | 2005-07-28 | 2006-07-20 | Caspase inhibitor prodrugs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009502922A true JP2009502922A (ja) | 2009-01-29 |
| JP2009502922A5 JP2009502922A5 (cg-RX-API-DMAC7.html) | 2009-09-03 |
Family
ID=37709070
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008523976A Pending JP2009502922A (ja) | 2005-07-28 | 2006-07-20 | カスパーゼ阻害剤プロドラッグ |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US7879891B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1910379B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2009502922A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20080038369A (cg-RX-API-DMAC7.html) |
| CN (1) | CN101268084A (cg-RX-API-DMAC7.html) |
| AT (1) | ATE529430T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2006276096A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2616337A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL188997A0 (cg-RX-API-DMAC7.html) |
| NO (1) | NO20081050L (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ566022A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2427582C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2007015931A2 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA200801172B (cg-RX-API-DMAC7.html) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20050159A1 (es) | 2003-05-27 | 2005-04-19 | Vertex Pharma | Derivados de acido 3-[2-(3-amino-2-oxo-2h-piridin-1-il)-acetilamino]-4-oxo-pentanoico como inhibidores de caspasa |
| PL217743B1 (pl) * | 2004-05-15 | 2014-08-29 | Vertex Pharma | Zastosowanie inhibitorów ICE/kaspazy-1 do leczenia napadów i konwulsji w epilepsji oraz zawierające je kompozycja farmaceutyczna i zestaw |
| WO2006057961A1 (en) * | 2004-11-24 | 2006-06-01 | Vertex Pharmaceuticals Incorporated | 3-[2-(3-acylamino-2-oxo-2h-pyridin-1-yl)-acetylamino]-4-oxo-pentanoic acid derivatives and their use as caspase inhibitors |
| JP5249770B2 (ja) | 2005-11-03 | 2013-07-31 | バーテックス ファーマシューティカルズ インコーポレイテッド | キナーゼインヒビターとして有用なアミノピリジン |
| KR20090099886A (ko) * | 2008-03-18 | 2009-09-23 | 주식회사 엘지생명과학 | 캐스파제 저해제의 프로드럭 |
| US8518942B2 (en) | 2008-08-06 | 2013-08-27 | Buck Institute For Research On Aging | Caspase inhibitors and uses thereof |
| ES2423668T3 (es) * | 2009-05-22 | 2013-09-23 | Abbvie Inc. | Moduladores de receptores 5-HT y métodos de uso de los mismos |
| RU2542988C2 (ru) * | 2009-07-31 | 2015-02-27 | Глоубал Элаенс Фор Тб Драг Дивелопмент | Нитроимидазооксазины и их применения при противотуберкулезной терапии |
| NZ598165A (en) * | 2009-07-31 | 2013-05-31 | Global Alliance For Tb Drug Dev | Nitroimidazooxazine and nitroimidazooxazole analogues and their uses |
| WO2011146089A1 (en) * | 2010-05-21 | 2011-11-24 | Abbott Laboratories | Modulators of 5-ht receptors and methods of use thereof |
| CN101979403A (zh) * | 2010-09-13 | 2011-02-23 | 沈陵陵 | 新型半胱氨酸天冬氨酸广谱蛋白酶抑制剂及其制备方法和用途 |
| US9956260B1 (en) | 2011-07-22 | 2018-05-01 | The J. David Gladstone Institutes | Treatment of HIV-1 infection and AIDS |
| CN107793434B (zh) * | 2016-09-07 | 2022-05-24 | 帝斯曼知识产权资产管理有限公司 | 用于制备经取代的咪唑并噻唑酮的方法 |
| KR102437095B1 (ko) * | 2019-04-19 | 2022-08-26 | 주식회사 엘지화학 | 캐스파제 저해제의 프로드럭 |
| CN113767097B (zh) | 2019-04-30 | 2025-03-14 | 株式会社Lg化学 | 半胱天冬酶抑制剂的前药 |
| US12257341B2 (en) | 2019-05-31 | 2025-03-25 | Lg Chem, Ltd. | Injectable composition containing prodrug of caspase inhibitors, and preparation method therefor |
| US20220226306A1 (en) | 2019-05-31 | 2022-07-21 | Lg Chem, Ltd. | Composition for caspase inhibitor prodrug injection |
| KR102670554B1 (ko) | 2022-01-04 | 2024-05-30 | 주식회사 이노보테라퓨틱스 | 캐스파제 저해제로서의 신규한 이소인돌리논 유도체 화합물 |
| WO2025221068A1 (ko) * | 2024-04-19 | 2025-10-23 | (주)노보메디슨 | 심장질환의 예방 또는 치료를 위한 캐스파제 저해제 |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999046248A1 (en) * | 1998-03-09 | 1999-09-16 | Vertex Pharmaceuticals Incorporated | 1,2-diazepane derivatives as interleukin-1beta converting enzyme inhibitors |
| WO1999047545A2 (en) * | 1998-03-19 | 1999-09-23 | Vertex Pharmaceuticals Incorporated | Inhibitors of caspases |
| WO2000001666A1 (en) * | 1998-07-02 | 2000-01-13 | Idun Pharmaceuticals, Inc. | C-TERMINAL MODIFIED OXAMYL DIPEPTIDES AS INHIBITORS OF THE ICE/ced-3 FAMILY OF CYSTEINE PROTEASES |
| WO2001010383A2 (en) * | 1999-08-06 | 2001-02-15 | Vertex Pharmaceuticals Incorporated | Caspase inhibitors and uses thereof |
| WO2001042216A2 (en) * | 1999-12-08 | 2001-06-14 | Vertex Pharmaceuticals Incorporated | Caspase inhibitors and uses thereof |
| WO2001072707A2 (en) * | 2000-03-29 | 2001-10-04 | Vertex Pharmaceuticals Incorporated | Carbamate caspase inhibitors and uses thereof |
| JP2003534320A (ja) * | 2000-05-19 | 2003-11-18 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ice阻害剤のプロドラッグ |
| WO2004002961A1 (en) * | 2002-06-28 | 2004-01-08 | Vertex Pharmaceuticals Incorporated | Caspase inhibitors and uses thereof |
| WO2004106304A2 (en) * | 2003-05-27 | 2004-12-09 | Vertex Pharmaceuticals Incorporated | 3 - [2- (3-amino-2-oxo-2h-pyridin-1-yl) - acetylamino] - 4- oxo-pentanoic acid derivatives and their use as caspase inhibitors |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5874424A (en) | 1995-12-20 | 1999-02-23 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β converting enzyme |
| SU1441748A1 (ru) * | 1987-03-04 | 1995-09-10 | Пермский государственный университет | 3-(4-бромфенил)-3а,4,6,6а-тетрагидрофуро[3,4-d]изоксазол-4-он, проявляющий противовоспалительную активность |
| SU1586154A1 (ru) * | 1988-09-15 | 2006-12-20 | Краснодарский политехнический институт | 3-(2,4-Дихлорфенил)-4-оксо-3a,4,6,6a-тетрагидрофуро-[3,4-d]изоксазол, проявляющий антигельминтную и анальгетическую активность |
| US5716929A (en) | 1994-06-17 | 1998-02-10 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1β converting enzyme |
| US5847135A (en) | 1994-06-17 | 1998-12-08 | Vertex Pharmaceuticals, Incorporated | Inhibitors of interleukin-1β converting enzyme |
| US5756466A (en) | 1994-06-17 | 1998-05-26 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1β converting enzyme |
| NZ291508A (en) * | 1994-08-30 | 1999-07-29 | Sankyo Co | Isoxazoles; preparation and medicaments |
| US5672584A (en) * | 1995-04-25 | 1997-09-30 | The University Of Kansas | Cyclic prodrugs of peptides and peptide nucleic acids having improved metabolic stability and cell membrane permeability |
| US5843904A (en) | 1995-12-20 | 1998-12-01 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1βconverting enzyme |
| JP2000501428A (ja) | 1996-09-12 | 2000-02-08 | アイドゥン ファーマシューティカルズ,インコーポレイテッド | 酵素のice/ced−3プロテアーゼファミリーを阻害する新規な三環式化合物 |
| JP3492703B2 (ja) | 1996-09-12 | 2004-02-03 | アイドゥン ファーマシューティカルズ,インコーポレイテッド | システインプロテアーゼのICE/ced―3ファミリーの阻害剤としてのC―末端変性(N―置換)―2―インドリルジペプチド |
| ATE310528T1 (de) | 1996-09-12 | 2005-12-15 | Idun Pharmaceuticals Inc | Hemmung der apoptose unter verwendung von inhibitoren der interleukin-1 beta converting enzym (ice)/ced-3 familie |
| US5968927A (en) | 1996-09-20 | 1999-10-19 | Idun Pharmaceuticals, Inc. | Tricyclic compounds for the inhibition of the ICE/ced-3 protease family of enzymes |
| US5919790A (en) | 1996-10-11 | 1999-07-06 | Warner-Lambert Company | Hydroxamate inhibitors of interleukin-1β converting enzyme |
| CA2268098A1 (en) | 1996-10-11 | 1998-04-23 | Warner-Lambert Company | Aspartate ester inhibitors of interleukin-1.beta. converting enzyme |
| US6184244B1 (en) | 1996-12-16 | 2001-02-06 | Idun Pharmaceuticals, Inc. | C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
| US6184210B1 (en) | 1997-10-10 | 2001-02-06 | Cytovia, Inc. | Dipeptide apoptosis inhibitors and the use thereof |
| DK1049703T3 (da) | 1998-01-20 | 2003-06-02 | Abbott Gmbh & Co Kg | N-[2-(5-benzyloxycarbonyl-amino-6-oxo-2--(4-fluorphenyl)-1,6-dihydro-1-pyrimidinyl)acetoxyl]-L-asparaginsyrealdehyd som en in vivo inhibitor af interleukin-1beta konverterende enzym |
| US6242422B1 (en) | 1998-10-22 | 2001-06-05 | Idun Pharmacueticals, Inc. | (Substituted)Acyl dipeptidyl inhibitors of the ice/ced-3 family of cysteine proteases |
| ATE344249T1 (de) | 1999-07-19 | 2006-11-15 | Merck Frosst Canada Ltd | Pyrazinone, diese verbindungen enthaltende zusammenstellungen |
| ATE472539T1 (de) | 2000-04-24 | 2010-07-15 | Vertex Pharma | Verfahren und zwischenprodukte zur herstellung von substituierten asparaginsäure-acetalen |
| NZ516918A (en) | 2000-05-23 | 2004-06-25 | Vertex Pharma | Caspase inhibitors and uses thereof |
| DE60131160T2 (de) | 2000-06-07 | 2008-08-07 | Vertex Pharmaceuticals Inc., Cambridge | Caspase-inhibitoren und ihre verwendungen |
| JP2004509120A (ja) | 2000-09-13 | 2004-03-25 | バーテックス ファーマシューティカルズ インコーポレイテッド | カスパーゼ阻害剤およびそれらの用途 |
| EP1341767B1 (en) | 2000-11-21 | 2007-04-11 | Vertex Pharmaceuticals Incorporated | Imidazole and benzimidazole caspase inhibitors and uses thereof |
| MXPA03009647A (es) | 2001-04-19 | 2004-01-29 | Vertex Pharma | Heterociclildicarbamidas como inhibidores de caspasa. |
| CA2447999C (en) | 2001-05-23 | 2011-04-26 | Vertex Pharmaceuticals Incorporated | Caspase inhibitors and uses thereof |
-
2006
- 2006-07-20 KR KR1020087004718A patent/KR20080038369A/ko not_active Ceased
- 2006-07-20 US US11/489,939 patent/US7879891B2/en not_active Expired - Fee Related
- 2006-07-20 AU AU2006276096A patent/AU2006276096A1/en not_active Abandoned
- 2006-07-20 AT AT06787963T patent/ATE529430T1/de not_active IP Right Cessation
- 2006-07-20 WO PCT/US2006/028174 patent/WO2007015931A2/en not_active Ceased
- 2006-07-20 CN CNA2006800345091A patent/CN101268084A/zh active Pending
- 2006-07-20 ZA ZA200801172A patent/ZA200801172B/xx unknown
- 2006-07-20 RU RU2008107576/04A patent/RU2427582C2/ru not_active IP Right Cessation
- 2006-07-20 JP JP2008523976A patent/JP2009502922A/ja active Pending
- 2006-07-20 EP EP06787963A patent/EP1910379B1/en not_active Expired - Lifetime
- 2006-07-20 CA CA002616337A patent/CA2616337A1/en not_active Abandoned
- 2006-07-20 NZ NZ566022A patent/NZ566022A/en not_active IP Right Cessation
-
2008
- 2008-01-24 IL IL188997A patent/IL188997A0/en not_active IP Right Cessation
- 2008-02-28 NO NO20081050A patent/NO20081050L/no not_active Application Discontinuation
-
2010
- 2010-12-17 US US12/971,649 patent/US8168798B2/en not_active Expired - Fee Related
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999046248A1 (en) * | 1998-03-09 | 1999-09-16 | Vertex Pharmaceuticals Incorporated | 1,2-diazepane derivatives as interleukin-1beta converting enzyme inhibitors |
| WO1999047545A2 (en) * | 1998-03-19 | 1999-09-23 | Vertex Pharmaceuticals Incorporated | Inhibitors of caspases |
| WO2000001666A1 (en) * | 1998-07-02 | 2000-01-13 | Idun Pharmaceuticals, Inc. | C-TERMINAL MODIFIED OXAMYL DIPEPTIDES AS INHIBITORS OF THE ICE/ced-3 FAMILY OF CYSTEINE PROTEASES |
| WO2001010383A2 (en) * | 1999-08-06 | 2001-02-15 | Vertex Pharmaceuticals Incorporated | Caspase inhibitors and uses thereof |
| WO2001042216A2 (en) * | 1999-12-08 | 2001-06-14 | Vertex Pharmaceuticals Incorporated | Caspase inhibitors and uses thereof |
| WO2001072707A2 (en) * | 2000-03-29 | 2001-10-04 | Vertex Pharmaceuticals Incorporated | Carbamate caspase inhibitors and uses thereof |
| JP2003534320A (ja) * | 2000-05-19 | 2003-11-18 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ice阻害剤のプロドラッグ |
| WO2004002961A1 (en) * | 2002-06-28 | 2004-01-08 | Vertex Pharmaceuticals Incorporated | Caspase inhibitors and uses thereof |
| WO2004106304A2 (en) * | 2003-05-27 | 2004-12-09 | Vertex Pharmaceuticals Incorporated | 3 - [2- (3-amino-2-oxo-2h-pyridin-1-yl) - acetylamino] - 4- oxo-pentanoic acid derivatives and their use as caspase inhibitors |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2006276096A1 (en) | 2007-02-08 |
| ZA200801172B (en) | 2009-04-29 |
| US20070155718A1 (en) | 2007-07-05 |
| US20110137037A1 (en) | 2011-06-09 |
| KR20080038369A (ko) | 2008-05-06 |
| NZ566022A (en) | 2011-04-29 |
| CN101268084A (zh) | 2008-09-17 |
| US7879891B2 (en) | 2011-02-01 |
| EP1910379B1 (en) | 2011-10-19 |
| RU2427582C2 (ru) | 2011-08-27 |
| NO20081050L (no) | 2008-04-28 |
| WO2007015931A3 (en) | 2007-06-07 |
| US8168798B2 (en) | 2012-05-01 |
| ATE529430T1 (de) | 2011-11-15 |
| RU2008107576A (ru) | 2009-09-10 |
| WO2007015931A2 (en) | 2007-02-08 |
| EP1910379A2 (en) | 2008-04-16 |
| CA2616337A1 (en) | 2007-02-08 |
| IL188997A0 (en) | 2008-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8168798B2 (en) | Caspase inhibitor prodrugs | |
| KR102680164B1 (ko) | Rock 억제제로서의 페닐아세트아미드 | |
| TWI405761B (zh) | 適合作為傑納斯激酶(janus kinase)抑制劑之氮雜吲哚 | |
| JP4107687B2 (ja) | 置換n―[(アミノイミノメチル又はアミノメチル)フェニル]プロピルアミド | |
| TWI721335B (zh) | 鹵代烯丙基胺類ssao/vap-1抑制劑及其用途 | |
| JP7447080B2 (ja) | Pad4阻害剤としての置換チエノピロール | |
| JP2021534108A (ja) | Pad酵素のインドールおよびアザインドール阻害剤 | |
| MX2008012860A (es) | Desazapurinas de utilidad como inhibidores de janus cinasas. | |
| CN101778825A (zh) | 适用作詹纳斯激酶抑制剂的n-杂环类化合物 | |
| JP6805172B2 (ja) | ヒストンデアセチラーゼ阻害薬及び組成物並びにそれらの使用の方法 | |
| JP6811233B2 (ja) | Tnfアルファの修飾因子として有用な環状化合物 | |
| AU758237B2 (en) | Thrombin inhibitors | |
| JP2004514671A (ja) | イミダゾールおよびベンゾイミダゾールカスパーゼのインヒビターならびにそれらの使用 | |
| CA3140017A1 (en) | Polyaromatic urea derivatives and their use in the treatment of muscle diseases | |
| AU2015311362B2 (en) | Pyrazolo[3,4-c]pyridine derivatives | |
| US6610701B2 (en) | Thrombin inhibitors | |
| CN113754635A (zh) | 稠环类化合物及其制备方法和用途 | |
| AU4470600A (en) | Thrombin inhibitors | |
| US6350745B1 (en) | Thrombin inhibitors | |
| HK1121750A (en) | Caspase inhibitor prodrugs | |
| MX2008001360A (en) | Caspase inhibitor prodrugs | |
| WO1999032459A1 (en) | Chymase inhibitors | |
| HRP960396A2 (en) | Polymorphs of the prodrug 6-n-(l-ala-l-ala)-trovafloxacin | |
| HK1146057A (en) | N-heterocyclic compounds useful as inhibitors of janus kinases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090710 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090710 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120207 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20120208 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120502 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120511 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120606 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120613 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120706 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120713 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120806 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20120806 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130325 |